MARKET

AGIO

AGIO

Agios Pharmaceuticals Inc
NASDAQ
33.93
+0.71
+2.14%
Opening 13:16 02/18 EST
OPEN
33.50
PREV CLOSE
33.22
HIGH
34.84
LOW
33.18
VOLUME
319.60K
TURNOVER
--
52 WEEK HIGH
62.58
52 WEEK LOW
24.69
MARKET CAP
1.94B
P/E (TTM)
2.915
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at AGIO last week (0210-0214)?
Weekly Report · 1d ago
Analysts Offer Insights on Healthcare Companies: Zoetis (ZTS), Agios Pharma (AGIO) and Dexcom (DXCM)
TipRanks · 1d ago
Agios Pharmaceuticals: Liver Toxicity Issues May Threaten Thalassemia Approval (Rating Downgrade)
Seeking Alpha · 3d ago
Agios Pharmaceuticals price target lowered to $74 from $75 at Scotiabank
TipRanks · 4d ago
Scotiabank Sticks to Its Buy Rating for Agios Pharma (AGIO)
TipRanks · 4d ago
AGIOS PHARMACEUTICALS INC <AGIO.O>: LEERINK PARTNERS CUTS TARGET PRICE TO $51 FROM $53
Reuters · 4d ago
Agios Pharma (AGIO) Receives a Buy from RBC Capital
TipRanks · 4d ago
Agios' Q4 Loss Wider Than Expected, Pyrukynd Drives Revenues
Barchart · 4d ago
More
About AGIO
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of alpha- and beta- thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The Company is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD.

Webull offers Agios Pharmaceuticals Inc stock information, including NASDAQ: AGIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AGIO stock methods without spending real money on the virtual paper trading platform.